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Abstract
Background: Sertoli-Leydig cell tumours of the ovary
account for only 0.2% of malignant ovarian tumours.
Two-thirds of all patients become apparent due to the
tumour’s hormone production.
Methods: A 41-year-old patient (gravida 4, para 4)
presented with dyspnoea, enlarged abdominal girth
and melaena. Diagnostic imaging was suspicious for
an ovarian cancer. The standard tumour marker for
ovarian cancer (CA 125) was elevated to 984 U/mL.
Results: Surgical exploration of the abdomen
revealed a mouldering tumour of both adnexes
extending to the level of the navel. Frozen sections
showed an undifferentiated carcinoma of unknown
origin. Radical surgery was performed. The final his-
tological report described a malignant sex-cord stro-
ma tumour, a Sertoli-Leydig cell tumour, emanating
from both ovaries. Analysis of preoperative blood
serum showed elevated levels of CYFRA 21-1
(10.4 ng/mL), neuron-specific enolase (36.2 ng/mL),
oestradiol (485 pg/mL) and CA-125 (984 U/mL). Adju-
vant chemotherapy and regional hyperthermia were
performed due to the malignant potential and incom-
plete resection of the tumour.
Conclusions: Undifferentiated Sertoli-Leydig cell
tumours show a poor clinical course. As only two-
thirds of patients with this rare disease present with
elevated hormone levels, new markers deserve fur-
ther investigation to offer more specific, individuali-
sed tumour monitoring.
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Sertoli-Leydig cell tumours are classified as sex-cord
stromal tumours. They account for only 0.2% of
malignant ovarian tumours and are often found uni-
laterally (1). Synonyms in the literature are arrheno-
blastoma, androblastoma and gonadal stromal
tumour of the android type. Most of these tumours
are described in young adults and less than 10%
occur prior to menarche or after menopause (2). Two-
thirds of all patients are diagnosed with this rare dis-
ease due to the tumour’s hormone production (3).
A 41-year-old patient (IV gravida, IV para) presented
with dyspnoea, enlarged abdominal girth and mela-
ena. On physical examination, the abdomen was dis-
tended with a fluid wave. Auscultation showed
decreased breath sounds over the basal lungs and
dullness to percussion suspicious for pleural effusion.
Gynaecological ultrasound and a computed tomo-
graphy scan of the abdomen and lung revealed a
more than 30-cm ovarian tumour with peritoneal car-
cinosis and ascites. There was bilateral pleural effu-
sion, but no signs of pulmonary nodules or other
distant metastases. The standard tumour marker for
ovarian cancer (CA 125) was elevated to 984 U/mL
(Table 1). Preoperative colonoscopy did not show a
pathologic finding except for polyposis. Bilateral
chest tubes were placed to relieve the pleural effu-
sion. Cytological analysis of the fluid was unremark-
able. Surgical exploration revealed a mouldering,
extremely soft tumour of the right adnex extending to
the level of the navel and a 7-cm smooth tumour of
the left adnex (Figure 1). Frozen sections were com-
patible with a poorly differentiated carcinoma of
unknown primary origin. Hysterectomy, adnexec-
tomy, appendectomy, omentectomy, peritonectomy
of the lesser pelvis and anterior resection of the sig-
moid colon and rectum were performed, reducing the
size of the tumour to approximately 1 cm, with a
residual mass in the mesenterium of the small intes-
tine. Due to low preoperative haemoglobin (78 g/L), a
need for intraoperative blood transfusions and
unclear histology, a lymphonodectomy was discount-
ed. The final histologic report based on analysis of
multiple tissue samples and results for immunohisto-
chemical stains (including keratin, inhibin, calretinin,
oestrogen and progesterone receptor) led to a diag-
nosis of a poorly differentiated Sertoli-Leydig cell
tumour involving both ovaries. The tumour infiltrated
the omentum, uterus, appendix and rectum. Post-
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Table 1 Serum markers for tumour monitoring.
Serum marker Preoperative 9-month follow-up Normal values
Immunology
CYFRA 21-1, ng/mL 10.4 -0.5 -3.3
NSE, ng/mL 36.2 12.3 0–16.3
CA 125, U/mL 984 3.4 0.0–35.0
CA 72-4, U/mL 0.8 0.6 -7.0
CEA, ng/mL -1.0 -0.1 -1.0
AFP, ng/mL 1.6 3.3 -15.0
Endocrinology
HCG-b, mIU/mL -2 -2 -2
Oestradiol, pg/mL 485 18.2 -10–300
Testosterone, ng/mL 0.2 -0.8 -0.8 ng/mL
Serum markers analysed preoperatively and at clinical follow-up 9 months after primary diagnosis of the Sertoli-Leydig cell
tumour. CYFRA, NSE, oestradiol and CA 125 seem to be suitable markers to monitor the clinical course of this patient’s
disease.
Figure 1 Clinical presentation and macroscopic tumour
appearance.
(A) Preoperative photograph of the patient: the abdomen is
distended compared to the cachectic body. (B) The intra-
operative situs shows the abdomen filled with a mouldering
tumour and bloody ascites. (C) The right adnex consists of
a more than 30-cm crumbly tumour: frozen section shows a
poorly differentiated carcinoma of unknown primary origin.
operative tumour stage was classified as pT3b, pNx,
pMx, FIGO IIIB. Retrospective analysis of preoperative
serum showed elevated levels of CYFRA 21-1
(10.4 ng/mL), neuron specific enolase (NSE; 36.2
ng/mL), oestradiol (485 pg/mL) and CA 125 (984 U/mL)
(Table 1). Adjuvant chemotherapy with eight cycles of
cisplatin 40 mg/m2/day, etoposide 100 mg/m2/day and
ifosfamide 1800 mg/m2/day for days 1–4, in combi-
nation with regional hyperthermia, was chosen
because of the malignant potential and incomplete
resection of the tumour.
At 1-year follow-up, no recurrent abdominal mass
could be identified either by physical examination or
by a computed tomography scan of the abdomen.
Serum markers were analysed on a 3-monthly base,
and so far show no signs of recurrence.
Sertoli-Leydig cell tumours account for 0.2% of
ovarian neoplasms (1). They are classified as one of
five histopathological types: well, intermediately or
poorly differentiated, with a retiform component or
with heterologous elements (gastrointestinal-type
epithelium, hepatocytes, skeletal muscle or cartilage)
(4). They consist of Sertoli and Leydig cells in varying
proportions and varying differentiation. Poorly differ-
entiated Sertoli-Leydig cell tumours are sarcomatoid
in appearance (5). Sertoli and Leydig cells can stain
positive for testosterone and oestradiol (6). Areas
with Sertoli tumour cells are positive for vimentin and
may express keratins, but are typically negative for
epithelial membrane antigen (EMA), placenta-like
alkaline phosphatase (PLAP), carcinoembryonic anti-
gen (CEA), CA 19.9, CA 125 and S-100 protein (7). Ley-
dig cells are predominantly positive for vimentin and
a-inhibin and stain negative for keratins (8). In our
case, the tumour cells expressed keratin (C), inhibin
(D) and calretinin (E), as well as oestrogen receptor
(F) and progesterone receptor (G) (Figure 2).
Approximately 70%–75% of Sertoli-Leydig cell
tumours occur in young adults, with a mean age of
25 years at primary diagnosis (2). There are six case
reports in the literature describing this rare disease in
postmenopausal women (9–14). Commonly, Sertoli-
Leydig cell tumours are detected at an early stage
(80% stage Ia). Only less than 3% have spread beyond
the ovary (15). Metastases are predominantly
described in the omentum, the abdominal lymph
nodes and the liver. Nonetheless, one case of a
metastasis in the frontal sinus has been reported (16).
Hardly ever are both ovaries involved. A review of 207
cases showed an incidence of 1.4% of bilateral Ser-
toli-Leydig cell tumour (17). In this review, all well-
differentiated tumours proved benign (18), whereas
11% of intermediately and 58% of poorly differen-
tiated tumours showed malignant behaviour. In the
same collective, malignant behaviour was observed
in 19% of patients with heterologous tumour ele-
ments (17). Moderately and undifferentiated tumours
with malignant potential show a significantly poorer
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Figure 2 Tumour histology.
Low-power view of the Sertoli-Leydig cell tumour: (A) right and (B) left ovary (haematoxylin and eosin staining, original
magnification 2.5=). Immunohistochemistry reveals expression of (C) keratin, (D) inhibin (particularly in Leydig cells), (E)
calretinin (particularly in the poorly differentiated Sertoli component), (F) oestrogen receptor and (G) progesterone receptor
(magnification 40=).
clinical course compared to well-differentiated
tumours. Nonetheless, an analysis of 64 intermediate
and poorly differentiated Sertoli-Leydig cell tumours
described a 5- and 10-year survival rate of 92% (19).
If recurrence occurs, it mainly appears within the first
year after primary diagnosis, typically in the perito-
neal space or retroperitoneal lymph nodes. A retro-
spective study by Chan et al. analysed prognostic
factors responsible for survival in sex-cord stromal
tumours. They reported that age -50 years, small
tumour size and absence of residual disease were
important predictors of improved survival (20).
The majority of patients become apparent because
of abdominal enlargement or pain caused by the
enormous size of the tumour (13, 15), which is an
average of 5–20 cm in diameter. Approximately two-
thirds of patients present with elevated hormone
levels. Typical signs of elevated oestrogen or testos-
terone levels are mild virilisation or irregular periods.
In this context, 35% of all women show symptoms of
androgen excess indicated by acne, temporal balding,
progressive masculinisation of veins, deepening of
the voice, disappearance of female body contours or
enlargement of the clitoris (15). These patients typi-
cally have elevated testosterone levels. The endo-
metrium can be affected by oestrogen synthesis
induced by peripheral aromatase or by direct oestro-
gen production by the tumour.
In the case presented here, there were no obvious
clinical signs of elevated hormone levels. Asked spe-
cifically, the patient mentioned period disorders (such
as menorrhoea) that could be explained by the high
oestrogen production by the tumour.
To detect tumour markers other than the known
standard for ovarian cancer (CA 125), we performed
detailed serum analysis, which revealed elevated oes-
trogen and normal testosterone levels, as well as ele-
vated levels of NSE and CYFRA, which, to the best of
our knowledge, have so far not been found in Sertoli-
Leydig cell tumour patients. CYFRA is known to be
elevated in ovarian malignancies (21). NSE is present
in all neurons and is therefore recognised as a mole-
cular marker of neuroendocrine tissue (22). In the
literature, NSE has been described in the context of
mature teratomas, immature teratomas, and dysger-
minomas (23). These tumour markers may also be
useful in our patient’s clinical follow-up and offer
more specific, individualised monitoring.
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Treatment recommended for Sertoli-Leydig cell
tumours varies with differentiation, tumour stage and
patient age. Treatment modalities discussed are often
controversial, as only a few studies have investigated
this rare disease. Definitive operative staging should
be performed in all Sertoli-Leydig cell tumours show-
ing intermediate and low differentiation, including
multiple biopsies and tissue from the omentum, as
well as evaluation of the pelvic and para-aortal lymph
nodes. Resection of normal lymph nodes is contro-
versial. If the tumour is highly differentiated and if
there is no sign of spread beyond the ovary involved
in a young woman, unilateral adnexectomy might be
justified. In our case the patient presented with a
tumour of low differentiation at an advanced stage
with unknown primary origin. Therefore, surgery
involving hysterectomy, adnexectomy, appendecto-
my, omentectomy, peritonectomy of the lesser pelvis
and anterior resection of the sigmoid colon and rec-
tum was performed to reduce the tumour mass.
The benefit of adjuvant radio- or chemotherapy is
not proven, but may be considered in cases of incom-
plete tumour resection (24). Because of the low dif-
ferentiation of the tumour, the residual tumour mass
and the advanced stage, chemotherapy with cisplatin,
etoposide and ifosfamide combined with hyperther-
mia according to the MAKEI protocol was chosen for
this patient. Chemotherapy regimes with cyclophos-
phamide in combination with either cisplatin and
doxorubicin (25) or vincristine and actinomycin D (26)
have also proven useful in individual cases. Hormonal
manipulation has been even used as a therapeutic
approach (27).
This case of a bilateral tumour in a perimenopausal
woman demonstrates different rare aspects for Ser-
toli-Leydig cell tumours. Unlike most cases, this
patient showed normal androgen but elevated oestro-
gen serum levels. We also found elevated serum lev-
els of NSE and CYFRA, which, to the best of our
knowledge, is a new finding in the context of Sertoli-
Leydig cell tumours. As only two-thirds of patients
with this rare disease present with elevated hormone
levels, these two markers deserve further investiga-
tion, because they may be suitable for more specific,
individualised tumour monitoring.
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